Journal article
Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: Factors affecting trough plasma concentrations
W Jeong, GI Snell, BJ Levvey, GP Westall, C Orla Morrissey, R Wolfe, S Ivulich, CF Neoh, MA Slavin, DCM Kong
Journal of Antimicrobial Chemotherapy | OXFORD UNIV PRESS | Published : 2018
DOI: 10.1093/jac/dkx440
Abstract
Objectives: This study describes therapeutic drug monitoring (TDM) of posaconazole suspension and modified release (MR) tablets in lung transplant (LTx) recipients and evaluates factors that may affect posaconazole trough plasma concentration (C min ). Methods: A single-centre, retrospective study evaluating posaconazole C min in LTx recipients receiving posaconazole suspension or MR tablets between January 2014 and December 2016. Results: Forty-seven LTx patients received posaconazole suspension, and 78 received the MR tablet formulation; a total of 421 and 617 C min measurements were made, respectively. Posaconazole was concurrently administered with proton pump inhibitor in≥90% of patient..
View full abstractGrants
Funding Acknowledgements
C. O. M. has received grants from Merck Sharp and Dohme (MSD) and Gilead Sciences, has sat on advisory boards for MSD and has received honoraria from Pfizer. M. A. S. has received grants from Pfizer, MSD and Gilead Sciences. D. C. M. K. has sat on advisory boards for Pfizer and MSD, and has received financial/travel support unrelated to the current work from Roche, Pfizer and MSD. All other authors: none to declare.